Penumbra PEN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Thrombectomy | $975.29M+2.9% | $947.92M+3.8% | $913.35M+3.7% | $881.07M+3.1% | $854.32M+4.8% | |
| Revenue by Geography | ||||||
| United States | $1.13B+3.6% | $1.09B+4.9% | $1.04B+4.9% | $991.92M+4.5% | $949.28M+5.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Penumbra break its business down?
- Penumbra (PEN) reports revenue by product across 3 parts — Embolization and Access, Embolization and Other and Thrombectomy. Each is extracted from the segment footnotes and tracked over time.
- Where does Penumbra's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Penumbra's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
